These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

256 related items for PubMed ID: 28283573

  • 1. Genetically encoded photocross-linkers determine the biological binding site of exendin-4 peptide in the N-terminal domain of the intact human glucagon-like peptide-1 receptor (GLP-1R).
    Koole C, Reynolds CA, Mobarec JC, Hick C, Sexton PM, Sakmar TP.
    J Biol Chem; 2017 Apr 28; 292(17):7131-7144. PubMed ID: 28283573
    [Abstract] [Full Text] [Related]

  • 2. The major determinant of exendin-4/glucagon-like peptide 1 differential affinity at the rat glucagon-like peptide 1 receptor N-terminal domain is a hydrogen bond from SER-32 of exendin-4.
    Mann RJ, Nasr NE, Sinfield JK, Paci E, Donnelly D.
    Br J Pharmacol; 2010 Aug 28; 160(8):1973-84. PubMed ID: 20649595
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Crystal structure of the ligand-bound glucagon-like peptide-1 receptor extracellular domain.
    Runge S, Thøgersen H, Madsen K, Lau J, Rudolph R.
    J Biol Chem; 2008 Apr 25; 283(17):11340-7. PubMed ID: 18287102
    [Abstract] [Full Text] [Related]

  • 6. Structural Determinants of Binding the Seven-transmembrane Domain of the Glucagon-like Peptide-1 Receptor (GLP-1R).
    Yang D, de Graaf C, Yang L, Song G, Dai A, Cai X, Feng Y, Reedtz-Runge S, Hanson MA, Yang H, Jiang H, Stevens RC, Wang MW.
    J Biol Chem; 2016 Jun 17; 291(25):12991-3004. PubMed ID: 27059958
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Dynamics of GLP-1R peptide agonist engagement are correlated with kinetics of G protein activation.
    Deganutti G, Liang YL, Zhang X, Khoshouei M, Clydesdale L, Belousoff MJ, Venugopal H, Truong TT, Glukhova A, Keller AN, Gregory KJ, Leach K, Christopoulos A, Danev R, Reynolds CA, Zhao P, Sexton PM, Wootten D.
    Nat Commun; 2022 Jan 10; 13(1):92. PubMed ID: 35013280
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Differential structural properties of GLP-1 and exendin-4 determine their relative affinity for the GLP-1 receptor N-terminal extracellular domain.
    Runge S, Schimmer S, Oschmann J, Schiødt CB, Knudsen SM, Jeppesen CB, Madsen K, Lau J, Thøgersen H, Rudolph R.
    Biochemistry; 2007 May 15; 46(19):5830-40. PubMed ID: 17444618
    [Abstract] [Full Text] [Related]

  • 11. The peptide agonist-binding site of the glucagon-like peptide-1 (GLP-1) receptor based on site-directed mutagenesis and knowledge-based modelling.
    Dods RL, Donnelly D.
    Biosci Rep; 2015 Nov 23; 36(1):e00285. PubMed ID: 26598711
    [Abstract] [Full Text] [Related]

  • 12. Two distinct domains of the glucagon-like peptide-1 receptor control peptide-mediated biased agonism.
    Lei S, Clydesdale L, Dai A, Cai X, Feng Y, Yang D, Liang YL, Koole C, Zhao P, Coudrat T, Christopoulos A, Wang MW, Wootten D, Sexton PM.
    J Biol Chem; 2018 Jun 15; 293(24):9370-9387. PubMed ID: 29717000
    [Abstract] [Full Text] [Related]

  • 13. A model for receptor-peptide binding at the glucagon-like peptide-1 (GLP-1) receptor through the analysis of truncated ligands and receptors.
    Al-Sabah S, Donnelly D.
    Br J Pharmacol; 2003 Sep 15; 140(2):339-46. PubMed ID: 12970080
    [Abstract] [Full Text] [Related]

  • 14. α-Helix or β-Turn? An Investigation into N-Terminally Constrained Analogues of Glucagon-like Peptide 1 (GLP-1) and Exendin-4.
    Oddo A, Mortensen S, Thøgersen H, De Maria L, Hennen S, McGuire JN, Kofoed J, Linderoth L, Reedtz-Runge S.
    Biochemistry; 2018 Jul 17; 57(28):4148-4154. PubMed ID: 29877701
    [Abstract] [Full Text] [Related]

  • 15. Nonconventional glucagon and GLP-1 receptor agonist and antagonist interplay at the GLP-1 receptor revealed in high-throughput FRET assays for cAMP.
    Chepurny OG, Matsoukas MT, Liapakis G, Leech CA, Milliken BT, Doyle RP, Holz GG.
    J Biol Chem; 2019 Mar 08; 294(10):3514-3531. PubMed ID: 30622136
    [Abstract] [Full Text] [Related]

  • 16. Identification of N-Terminally Diversified GLP-1R Agonists Using Saturation Mutagenesis and Chemical Design.
    Longwell CK, Hanna S, Hartrampf N, Sperberg RAP, Huang PS, Pentelute BL, Cochran JR.
    ACS Chem Biol; 2021 Jan 15; 16(1):58-66. PubMed ID: 33307682
    [Abstract] [Full Text] [Related]

  • 17. The isolated N-terminal domain of the glucagon-like peptide-1 (GLP-1) receptor binds exendin peptides with much higher affinity than GLP-1.
    López de Maturana R, Willshaw A, Kuntzsch A, Rudolph R, Donnelly D.
    J Biol Chem; 2003 Mar 21; 278(12):10195-200. PubMed ID: 12524435
    [Abstract] [Full Text] [Related]

  • 18. Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells.
    Göke R, Fehmann HC, Linn T, Schmidt H, Krause M, Eng J, Göke B.
    J Biol Chem; 1993 Sep 15; 268(26):19650-5. PubMed ID: 8396143
    [Abstract] [Full Text] [Related]

  • 19. Second extracellular loop of human glucagon-like peptide-1 receptor (GLP-1R) has a critical role in GLP-1 peptide binding and receptor activation.
    Koole C, Wootten D, Simms J, Miller LJ, Christopoulos A, Sexton PM.
    J Biol Chem; 2012 Feb 03; 287(6):3642-58. PubMed ID: 22147710
    [Abstract] [Full Text] [Related]

  • 20. Molecular Characterisation of Small Molecule Agonists Effect on the Human Glucagon Like Peptide-1 Receptor Internalisation.
    Thompson A, Stephens JW, Bain SC, Kanamarlapudi V.
    PLoS One; 2016 Feb 03; 11(4):e0154229. PubMed ID: 27100083
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.